electroCore (ECOR) is trading down at $10.13 (-0.10%), as of the latest quote. It operates in the Health Care sector.
| FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $811.5K | $993.0K | $2.39M | $3.50M | $5.45M | $8.59M | $16.0M | $25.2M | $32.0M |
| Growth (year over year) | — | +22.4% | +140.7% | +46.3% | +55.9% | +57.6% | +86.6% | +57.1% | +27.2% |
| Gross profit | $292.9K | $414.2K | $1.23M | $1.76M | $4.07M | $6.98M | $13.2M | $21.4M | $27.8M |
| Gross margin | 36.1% | 41.7% | 51.6% | 50.3% | 74.6% | 81.2% | 82.5% | 85.0% | 86.8% |
| Operating income | −$25.6M | −$54.6M | −$46.1M | −$24.7M | −$20.0M | −$22.9M | −$19.3M | −$12.2M | −$13.2M |
| Operating margin | −3160.3% | −5494.1% | −1928.2% | −707.9% | −367.7% | −266.2% | −120.2% | −48.3% | −41.1% |
| Net income | −$35.8M | −$55.8M | −$45.1M | −$23.5M | −$17.2M | −$22.2M | −$18.8M | −$11.9M | −$14.0M |
| Net margin | −4410.9% | −5621.7% | −1888.8% | −672.5% | −315.9% | −257.9% | −117.5% | −47.2% | −43.6% |
| EPS (diluted) | — | −$267.75 | −$346.50 | −$135.00 | −$65.40 | −$4.69 | −$3.42 | −$1.59 | −$1.65 |
| Balance sheet | |||||||||
| Cash and equivalents | $13.2M | $7.60M | $13.6M | $4.24M | $34.7M | $17.7M | $10.3M | $3.70M | $7.04M |
| Total assets | $39.2M | $73.5M | $35.5M | $31.5M | $42.8M | $24.8M | $16.1M | $20.5M | $18.7M |
| Total liabilities | $6.43M | $7.32M | $10.6M | $7.87M | $6.18M | $7.67M | $8.66M | $12.9M | $20.4M |
| Long-term debt | — | — | — | $1.10M | — | — | — | — | $6.61M |
| Shareholders' equity | −$90.1M | $65.6M | $24.3M | $23.0M | $36.6M | $17.1M | $7.44M | $7.54M | −$1.71M |
| Cash flow | |||||||||
| Operating cash flow | −$25.3M | −$47.1M | −$45.1M | −$20.1M | −$13.6M | −$16.6M | −$14.7M | −$6.95M | −$8.19M |
| Capital expenditure | $152.5K | $278.9K | $69.7K | — | — | — | $206.0K | — | $66.0K |
| Free cash flow | −$25.5M | −$47.4M | −$45.1M | — | — | — | −$14.9M | — | −$8.25M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $6.55M | $7.05M | $6.72M | $7.38M | $8.69M | $9.24M | $9.58M | $9.45M |
| Growth (year over year) | +45.4% | +35.7% | +23.4% | +20.2% | +32.6% | +31.2% | +42.6% | +28.0% |
| Gross profit | $5.49M | $6.05M | $5.71M | $6.44M | $7.47M | $8.17M | $8.36M | $8.18M |
| Gross margin | 83.8% | 85.9% | 84.9% | 87.3% | 86.0% | 88.4% | 87.3% | 86.5% |
| Operating income | −$2.65M | −$3.07M | −$3.82M | −$3.51M | −$2.88M | −$2.94M | −$5.32M | −$2.77M |
| Operating margin | −40.4% | −43.6% | −56.9% | −47.5% | −33.2% | −31.8% | −55.5% | −29.3% |
| Net income | −$2.50M | −$3.23M | −$3.85M | −$3.67M | −$3.40M | −$3.04M | −$5.27M | −$3.06M |
| Net margin | −38.1% | −45.8% | −57.4% | −49.7% | −39.2% | −32.8% | −55.0% | −32.4% |
| EPS (diluted) | −$0.31 | −$0.37 | −$0.47 | −$0.44 | −$0.40 | −$0.34 | −$0.59 | −$0.33 |
| Balance sheet | ||||||||
| Cash and equivalents | $4.93M | $3.70M | $3.78M | $3.37M | $7.86M | $7.04M | $4.85M | $8.50M |
| Total assets | $21.0M | $20.5M | $16.0M | $14.6M | $21.4M | $18.7M | $15.5M | $17.1M |
| Total liabilities | $11.6M | $12.9M | $11.7M | $13.4M | $22.5M | $20.4M | $21.2M | $19.9M |
| Long-term debt | — | — | — | — | $6.53M | $6.61M | $6.44M | $5.77M |
| Shareholders' equity | $9.46M | $7.54M | $4.37M | $1.11M | −$1.07M | −$1.71M | −$5.69M | −$2.79M |
| Cash flow | ||||||||
| Operating cash flow | −$1.36M | −$1.25M | −$4.36M | −$623.0K | −$1.67M | −$1.54M | −$3.01M | −$3.52M |
| Capital expenditure | — | — | $37.0K | $25.0K | $4.00K | $0 | $2.00K | $4.00K |
| Free cash flow | — | — | −$4.39M | −$648.0K | −$1.67M | −$1.54M | −$3.01M | −$3.52M |
From electroCore's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
electroCore, Inc. is a medical technology company based in Basking Ridge, New Jersey. electroCore was co-founded in 2005 by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD. The current chief executive officer is Daniel S. Goldberger. electroCore has one product called gammaCore, a non-invasive, commercially available product that uses vagus nerve stimulation.
Source: Wikipedia — ElectroCore
No recent news mentioning electroCore in our feed yet.